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Abstract: Leishmania are known to be auxotrophic for pteridines that are known to play a critical role 
in the parasites survival. In the present work the role of biopterin transporter in the growth of the 
parasite and infectivity in to macrophages has been worked out. The role of biopterin transporter in the 
susceptibility of Leishmania to antimonial compounds has also been demonstrated. This role has been 
verified by using attenuated strains of Leishmania with single, double, and triple (null) biopterin (BT1) 
mutants made by targeted gene replacement with specific antibiotic markers. Growth analysis of these 
mutants revealed that wild type, single and double knock out cell lines maintained high growth rates in 
the medium supplemented with biopterin and folate, whereas the triple knock out or null BT1 mutants 
were unable to grow in the absence of supplemental biopterin. Using wild type and null BT1 mutants, 
we examined the role of BT1 gene in infectivity and parasite survival. The cell lines with amplified 
BT1 gene showed increased infectivity and survival in the macrophages where as the cell lines with 
disrupted BT1 gene showed reduced infectivity and survival in the macrophages. We also examined 
the interaction between pteridine and antimonial compounds using recombinant Leishmania strains 
with reduced or absent biopterin transporter gene (BT1) alleles. No difference in susceptibility to 
Pentostam or Glucantime was observed in both wild type and BT1-knock out strains. However, pterin 
or folate supplementation resulted in reversal of Glucantime but not Pentostam susceptibility in both 
wild type and BT1-knock out strains. The reversal of Glucantime susceptibility by pterins in BT1-
knock out strains suggests that the effect may be exerted independently of biopterin transporter, 
possibly by blocking Glucantime uptake.  
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INTRODUCTION 
 
Leishmania are flagellated protozoa of the order 
kinetoplastida. They cause diseases ranging from a mild 
cutaneous form to fatal visceral infection. Pentavalent 
antimonial compounds, Glucantime and Pentostam are 
the drugs of choice for this disease. Emergence of 
resistance to these commonly used antimonials has led 
to the need of alternative chemotherapeutic approaches 
to combat and prevent the disease.  
The folate pathway has been the target of 
chemotherapeutic intervention in infectious diseases 
caused by phylogenetically related apicomplexan 
parasites as well as many bacterial pathogens. Several 
inhibitors, like sulfonamidies and sulfones, inhibitors of 
dihydropteroate synthetase (DHPS) and pyrimethamine, 
trimethoprim and methotrexate, inhibitors of 
dihydrofolate reductase (DHFR), have been used in the 
treatment of both malaria and toxoplasmosis[4, 13]. 
These inhibitors have been found to be ineffective 
against leishmaniasis[12, 22, 26]. Leishmania species are 
known to be auxotrophic for folate[19, 28-30]. However, 
Leishmania species have the ability to grow in a folate 
deficient medium supplemented with pterins thereby 
eliminating the folate requirement in the parasite[1]. 
Furthermore it has also been demonstrated that L. 
donovani promastigotes are capable of metabolizing 
biopterin to tetrahydrofolates unlike the mammalian 
host[2]. The precise pathway of conversion of pterins to 
folates is not known. It has been shown that pteridine 
reductase (PTR1) mediates the salvage of oxidized 
pteridines in Leishmania[3]. Purified PTR1 is capable of 
reducing both unconjugated (biopterin) and conjugated 
(folate pteridines from either the oxidized or the 
dihydrostate)[3]. The role of H4-biopterin in Leishmania 
is not known.  
Biopterin transporter gene (BT1) or   ORFG is 
present in the LD1 common region of Leishmania. This 
gene is universally amplified in all strains of 
Leishmania showing LD1 amplification. It codes for a 
transmembrane protein with 10 –12 putative membrane 
spanning domains. These regions are predicted to form 
amphiphilic α-helix or β strands typical of type IV 
integral proteins[24]. Database searches of protein and 
nucleic acid homologies revealed that BT1 has 34% 
amino acid similarity with ESAG10 gene from the 
Trypanosoma brucei VSG expresion site. The 45-kDa 
BT1 protein in Leishmania is consistently and 
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constitutively expressed in all the growth stages of the 
parasite [11]. Biopterin transport occurs exclusively via 
biopterin transporter 1 (BT1)[6, 20, 24]. The fact that 
parasite is capable of converting biopterin to 
tetrahydrofolates unlike the mammalian host provides a 
rational approach towards using this pathway as a drug 
target and further necessitates the need to characterize 
this drug target at the molecular level. 
In order to study the possible importance of 
biopterin transporter, we have used attenuated 
Leishmania strains with decreased or null biopterin 
transporter. The role of over expression or disruption of 
BT1 in the growth and infectivity of Leishmania has 
been worked out.  
The mechanism of action of pentavalent 
antimonials (Glucantime and Pentostam), the drugs of 
choice for the treatment of visceral leishmaniasis is 
poorly understood.  Recently it has been reported that 
Glucantime susceptibility can be partially reversed by 
biopterin[23]. Although the metabolic role of biopterin 
and closely related compounds is not yet fully 
elucidated, they have been implicated in a number of 
reactions, such as formation of unsaturated fatty acids, 
as cofactors in the first desaturation of stearic acid to 
oleate[8, 14]or as precursors of folate[2, 29]. Leishmania 
species are auxotrophic for pteridines, but they have the 
ability to grow in a folate-deficient medium 
supplemented with pterins, thereby eliminating the 
folate requirement of the parasite[20]. In the present 
study the possible interaction between pteridine and 
glucantime susceptibility has been worked out by using 
recombinant Leishmania strains with reduced or absent 
biopterin transporter gene (BT1) alleles.    
 
MATERIALS AND METHODS 
 
Cell culture: All mutants of BT1 transporter gene were 
derived from L. donovani strain LSB51.1 
(MHOM/SD/00/Khartoum). These attenuated strains 
were made by three rounds of targeted gene 
replacement [21] since this strain contains three copies of 
BT1, two copies within the LD1 locus on the 
chromosome 35 homologs and a single copy in the 
chromosome 27 rDNA locus. These knock out strains 
contain integrated puromycin, hygromycin and 
phleomycin drug resistance markers replacing the two 
BT1 alleles on 2.2-Mb chromosome 35 and one on 1.2-
Mb chromosome 27 respectively [21]. Promastigotes of 
wild type 51.1, Single knock out mutant (SKO) of this 
strain that retained two intact BT1 copies, one on 
chromosome 35 and other on chromosome 27, Double 
knock out mutant (DKO) of the strain 51.1 that lacked 
both chromosome 35 BT1 copies but contained the 
intact BT1 copy on the chromosome 27, Triple knock 
out mutant or BT1 null mutant termed TKO were 
produced from DKO mutant by replacing the remaining 
BT1 copy, were used for the present study.  
Promastigotes were grown at 22-24°C in M199 media 
(Gibco BRL) with 10% heat inactivated fetal bovine 
serum (FBS, Biological Industries, Israel). The triple 
knock out mutant (TKO) was maintained in the above 
media with BF solution (7.5 µM each of biopterin 
(Sigma), dihydrobiopterin (BH2, Schircks Laboratories, 
Jona, Switzerland), folate (Sigma) and dihydrofolate 
(FH2, Sigma). Biopterin and BH2 solutions were made 
in 40mM Hepes, pH 7.4/5 mM DTT while folate and 
FH2 were made in distilled water. L. donovani AG83 
(MHOM/IN/1983/AG83) strain was used for 
overexpression studies. 
Leishmania strains were maintained in medium M199 
(Gibco, BRL) with 10% foetal bovine serum (FBS) at 
22-24°C and were sub-cultured when the cells reached 
the stationary phase. 
 
Generation of BT1 overexpressing Leishmania 
strain: pSLαneoα, Leishmania expression vector was 
used to overexpress a 2.3 Kb BglII-NheI fragment of L. 
donovani BT1, (kindly provided by Marc Ouellette, 
Quebec, Canada). pSLαneoα-BT1 construct was 
transfected in the wild type L.donovani AG83 
(MHOM/IN/1983/AG83) strain  
 
(a)
 
 
 
 
   (b) 
 
Fig 1: Growth curve of the wild type 51.1, single 
knockout (SKO), double knock out (DKO), and 
triple knock out (TKO) strain of L. donovani in 
the absence of (a) or in the presence of (b) 
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7.5µM each of biopterin, dihydrobiopterin, folate 
and dihydrofolate. Approximately 2× 106 cells 
stationary phase promastigotes were inoculated 
into the medium and cell density was determined 
every 24h till 120h and plotted on a linear graph. 
Three replicate experiments were performed and 
similar results were obtained consistently. 
 
via electroporation as reported previously [21]. AG83 
strain contains two copies of BT1, within the LD1 locus 
on the chromosome 35 homologs. Transfected 
Leishmania was selected against 40 µg of G418. The 
strain was maintained in medium M199 (Gibco, BRL) 
with 10% FBS and 40 µg of G418 at 22-24ºC. 
Growth studies: Growth profile of wild strain LSB51.1 
and three transgenic strains with disrupted BT1 
transporter gene, single (SKO), double (DKO) and 
triple knock out (TKO) was studied by inoculating 
stationary phase cells at a density of ~2×106 cells/ml of 
the minimum essential medium with α modification [24] 
supplemented with biopterin and folate (7.5 µM each of 
biopterin, dihydrobiopterin, folate and dihydrofolate) 
while the other was grown in un-supplemented 
medium. Growth rates of each of the cultures were 
determined at 24h interval. Growth studies with each 
individual cell line have been done at least three times 
and similar results were obtained consistently. 
In vitro macrophage infection: The mouse monocyte-
macrophage cell line J774A.1 obtained from ATCC 
was cultured in RPMI-1640 medium with 10% FBS at 
37°C in a CO2 incubator with 5% O2 and 95% humidity. 
Macrophages (106 cells/ml) were plated in 60 mm tissue 
culture plate. In vitro infection of J774A.1 macrophages 
was done with 1×107 stationary phase promastigotes of 
either wild type or transgenic strains. After 3 h of 
infection, the medium was removed and replaced with 
fresh RPMI 1640 medium with  
10 % FBS in order to remove any free promastigotes. 
The cells were kept at 37°C for another 24 h. The plates 
in triplicate were taken out at the desired time intervals, 
washed with phosphate buffered saline (PBS), dried, 
fixed with methanol and stained with giemsa. The 
percentage infectivity was determined by counting 100 
macrophages by examining microscopically. Number of 
infected macrophages and number of amastigotes per 
100 macrophages was noted. Infectivity was also 
checked by infecting macrophages with radio-labelled 
L. donovani, labelled with tritiated thymidine. The 
results are mean ± SD of triplicate samples.  
STATISTICAL ANALYSIS 
 
All experiments were performed in triplicate. In the 
microscopic studies, a minimum of 200 cells was 
screened in each culture and the percentage of infected 
cells and the average number of amastigotes per 100 
infected cells was recorded. The results represent mean ± SD of triplicates. Student’s t-test was performed to 
determine the level of significance and p < 0.05 was 
considered to be significant.  
a 
 
b 
 
 
Fig 2: Comparison of infectivity of L. donovani LSB 
51.1, wild type strain, single (SKO), double 
(DKO), and triple (TKO) knock out mutants of 
BT1 transporter gene in J774A.1 murine 
macrophage cell line. 106 J774A.1 murine 
macrophage cells in RPMI1640 medium with 
10% heat inactivated foetal bovine serum (FBS) 
were infected with 107 stationary phase 
promastigotes of either wild type or transgenic 
leishmanial strains in a CO2 incubator with 5% 
O2 and 95% humidity. After 3h the medium was 
removed and replaced with fresh RPMI 1640 
medium with 10% FBS in order to remove any 
free promastigotes. The cells were incubated at 
37°C for another 24h. The plates were taken out 
at 24h interval, washed with PBS, dried, fixed 
with methanol and stained with Giemsa. The 
percentage infectivity was determined by 
counting 100 macrophages by microscopic 
examination. Percentage of infected 
macrophages and percentage of amastigotes per 
100 macrophages was noted. The results 
represent mean ± SD of triplicates. * indicates 
p>0.01<0.05, ** indicates p>0.001<0.01, *** 
indicates p value < 0.001. 
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RESULTS 
 
Growth rate analysis: A comparison of growth pattern 
of the wild type 51.1 and transgenic strains was done 
both in the medium supplemented with biopterin and 
folate (7.5µM each of biopterin, dihydrobiopterin, 
folate and dihydrofolate) and medium without any 
biopterin and folate supplement. Growth rate of each of 
the cell line was determined for a period of 120 h at an 
interval of 24 h. Figure1A shows the growth of all the 
strains in the absence of biopterin and folate and Fig1B 
shows the growth pattern of these leishmania strains in 
the presence of biopterin and folate. The doubling times 
of wild type, SKO, DKO and TKO were approximately 
56, 48, 56 and 120 hour respectively in the presence of 
supplemental biopterin and folate. In the absence of 
supplemental biopterin and folate, the doubling times 
were 67, 72, 96 and >120 hour respectively. The wild 
type strain 51.1 and SKO transgenic showed a similar 
growth pattern in both the media till 72 h time interval, 
thereafter i.e. at 96 h time point the cell density was 
∼1.5 times more in media supplemented with biopterin 
and folate. Strain DKO, on the other hand showed a 
substantial difference in the growth of the cells in the 
presence and absence of the supplemented medium 
(Fig1A-B). As early as 72 h of growth there was a 
significant increase in the growth of these cells in the 
media supplemented with biopterin and folate.  Each of 
the strain decreased in growth on removal of biopterin 
and folate. However the TKO strain, both in the 
presence and absence of the supplemented medium did 
not show any substantial change in the doubling time in 
both the media. The doubling time of TKO shifted to 
120 h in the presence of biopterin and folate whereas in 
the absence of these supplements the TKO ceased to 
grow after this time interval. Comparison of growth 
rates of the wild type 51.1 and TKO in the presence of 
biopterin and folate showed that though the initial cell 
density of the two strains was same, at 96 h, the cell 
density of wild type had  
(a) 
 
 (b) 
 
Fig 3: Infection of J774A.1 murine macrophage cell 
line with wild type L. donovani strain LSB 51.1 
and BT1 triple knock out (TKO). 106 J774A.1 
macrophages were plated per 60mm tissue 
culture plate. After this the macrophages were 
infected with 107 L. donovani either wild type 
51.1 strain or BT1 triple knock out (TKO) strain. 
After 3h of infection the medium in the plate was 
changed and the infection carried on till 12h and 
24h. A: represents number of infected 
macrophages and B: represents number of 
amastigotes/100 macrophages at 3, 12 and 24h 
after infection. The results represent mean ± SD 
of triplicates. 
  
reached 7.5×106 cells/ml whereas the cell density of 
TKO was only 3× 106 cells /ml. 
  
Co-relationship between BT1 targeted mutants and 
invasion and survival in macrophages: We tested the 
ability of these transgenic parasites with decreased 
expression of biopterin transporter to invade and 
survive in murine macrophages and compared this 
ability with that of the wild type strain 51.1. The effect 
of loss of one, two and all three BT1 copies on 
intracellular survival and invasion of macrophages is 
shown in Fig 2. A significant decrease in the number of 
parasitized cells was observed with the single 
(p>0.01<0.05), double (p<0.001) and triple 
(p>0.01<0.05) targeted BT1 mutants compared to wild 
type 51.1 following 24 h of infection. Similarly the 
number of amastigotes decreased drastically in SKO 
(p>0.01<0.05), DKO (p>0.001<0.01) and TKO 
(p>0.001<0.01) mutants. In case of triple targeted BT1 
mutant, TKO, a significant decrease in the parasitized 
cells and infectivity levels was observed as early as 12 
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 51.1              TKO          TKO
+B+F ++                   --             ++ 
h after infection. (Fig 3.A-B).  Infectivity levels 
decreased steadily to reach 40% after 24 h.  
 In order to make sure that reduction of triple 
targeted BT1 mutants to infect macrophages arose 
specifically from the lack of biopterin transporter, the 
medium was supplemented with 7.5 µM each of 
biopterin, dihydrobiopterin, folate and dihydrofolate to 
check if it restored both infectivity and replication of 
the parasites. Addition of biopterin and folate to the 
medium restored both infectivity and replication of 
triple knock out (TKO) to the same levels as wild type 
strain 51.1 after 24 h of infection (Fig. 4). However 
addition of biopterin and folate supplemented media to 
the strain 51.1 did not alter its infectivity and 
replication (Fig 4).  
Co-relationship between BT1 gene amplification and 
invasion and survival in macrophages: In order to 
find out a possible co-relationship, if any, exists 
between overexpression of BT1 gene and invasion and 
survival in macrophages, we used pSLαneoα-BT1 
construct transfected AG83 strain. This overexpressing 
strain was then tested for its ability to infect 
macrophages by using tritiated thymidine labelled 
parasites. Fig. 5 shows that BT1 overexpressing strain 
exhibited a significantly higher infectivity 
(p>0.01<0.05) when compared to the wild type strain 
having the presence of BT1 gene on the 2.2 Mb 
chromosome only and not as amplified copies.  
 
Interaction of pterins and pentavalent antimonials 
was examined in the knockout mutants:  Stationary 
phase promastigotes at a density of ~2×106 cells were 
inoculated into α-MEM[16] either with, or without, 
supplementation  
 
 
 
Fig 4: Infection of J774A.1 murine macrophage cell 
line with wild type L. donovani strain LSB 51.1 
and BT1 triple knock out (TKO) in the presence 
and absence of biopterin and folate (+B+F) and 
absence of biopterin and folate supplemented 
medium (-B-F). 106 J774A.1 macrophages were 
plated per tissue culture plate. After 3h the 
macrophages were infected with 107 L. donovani 
either the wild type 51.1 strain or TKO strain. 
Three hours later the medium was removed and 
infection was carried on for another 24h. 
Percentage of infected macrophages and 
amastigotes/ 100 macrophages was determined 
by microscopic examination of the Giemsa 
stained slides. The results represent mean  SD 
of triplicates. * indicates p>0.01<0.05, ** 
indicates p>0.001<0.01. 
 
with 7.5 µM each of biopterin, dihydrobiopterin, folate 
and dihydrofolate.  After 24 h, 200 µl of cell suspension 
was added to the wells of micro titer plates to which 
various concentrations of Pentostam (Welcome, UK) or 
Glucantime (Specia, France) were added.  The cells 
were counted after 72 h incubation.  The concentration 
that inhibited the growth of the promastigotes by 50% 
(IC50) was determined from a plot of cell number versus 
drug concentration. The IC50 for Pentostam was found 
to be 2 mg/ml for the wild type and the BT1 knockout 
strains. Addition of 7.5 µM each of biopterin, 
dihydrobiopterin, folate, and dihydrofolate did not 
affect the IC50 for Pentostam of the wild type and 
knockout strains (data not shown).  In contrast, pterin 
supplementation increased the IC50 of Glucantime from 
2 mg/ml to >7.5 mg/ml in LSB-51.1 wild type, SKO, 
DKO and TKO strains (data not shown).   
Biopterin and folate were tested individually to 
determine which of these pterins is responsible for the 
reduction in susceptibility to Glucantime in the LSB-
51.1 wild type and TKO strain. The Glucantime IC50 
values were >7.5 mg/ml for both the wild type and 
TKO strain with biopterin supplementation (7.5 µM 
each of biopterin and dihydrobiopterin) (data not 
shown). Similarly, addition of 7.5 µM each of folate 
and dihydrofolate resulted in a Glucantime IC50 value 
of >7.5 mg/ml for both the strains (data not shown).  
 
DISCUSSION 
 
The metabolic role of pterins in Leishmania is not 
known[26]. They have been implicated in a number of 
functions such as hydroxylation of phenylalanine and 
tyrosine in cleavage of ether lipids and biosynthesis of 
nitric oxide in other organisms[17]. However Leishmania 
does not have phenylalanine hydroxylase activity[18].  
Leishmania are known to convert pterins to tetra 
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hydrofolate[2]. In contrast to the mammalian hosts, 
Leishmania are pteridine auxotrophs and have an 
absolute requirement for an exogenous source[1, 19, 28-30]. 
Leishmania unlike the mammalian host they infect 
cannot synthesize the pteridine component of folate.  
Also, several species of Leishmania are capable of 
continual propagation in folate deficient media 
supplemented with biopterin[19, 28]. These studies were 
further supported by the fact that Leishmania is indeed 
capable of converting biopterin to tetrahydrofolate[2] 
and has evolved a complex pterdine salvage pathway 
that is capable of scavenging both conjugated and 
unconjugated pteridines[6]. Recent studies have shown 
that Leishmania require pteridines for survival besides 
folate[6, 21, 23]. Also the enzyme involved in the 
formation of H4 biopterin from quinonoid H4 biopterin 
in other organisms has a functional role in Crithidia and 
Leishmania[15, 3]. The existing data clearly indicates the 
critical importance of biopterin for the Leishmanial 
parasite. The disruption of BT1 gene has been achieved 
in L tarentolae[20], in L. donovani [21, 27] and in L. 
major[7]. In BT1 mutant strains biopterin uptake is 
completely abolished further suggesting that BT1 is 
likely the main transporter of Leishmania cells. 
Nonetheless pterin supplementation was essential  
 
 
 
Fig 5: Infection of J774A.1 murine macrophage cell 
line with wild type L. donovani strain AG83 and 
BT1 overexpressing AG83. 106 J774A.1 
macrophages were plated per 60mm tissue 
culture plate. The macrophages were infected 
with tritiated thymidine labelled, 107 L. 
donovani either wild type AG83 strain or BT1 
overexpressing strain. After 3 h of infection, the 
free parasites were washed out with serum free 
RPMI followed by addition of complete media 
and further incubation of 24 h. After 24 h 
incubation, cells were lysed with 1% Triton X 
100 and assayed for radioactivity counts using 
liquid scintillation counter. The result is a 
representative of three independent experiments 
done. * indicates p>0.01<0.05. 
for the growth of BT1 mutants. We were unable to 
obtain null mutants by targeted gene replacement in 
standard growth medium without added biopterin and 
folate. All recombinants selected without pteridine 
supplementation contained amplified copies of BT1 
gene in addition to knockout construct at the intended 
site[21]. Thus uptake of biopterin by BT1 appears critical 
for cell survival at physiological concentrations of 
biopterin. 
The BT1 null mutant (TKO) showed significantly 
slower growth as promastigotes, even in the presence of 
supplemental biopterin and folate, suggesting that their 
ability to grow in this medium is due to uptake via 
passive diffusion or a secondary  (low affinity) 
transporter[21, 27]. 
In order to further investigate the physiological role 
of BT1 transporter gene, BT1 knock out mutants were 
used. The physiological function of several Leishmania 
genes has been worked out using gene-targeting 
procedure[5, 11]. The present work shows the role of 
disruption of BT1 gene on the growth of Leishmania 
parasite. The role of over expression or disruption of 
biopterin transporter gene on the ability of the parasite 
to infect and survive in the macrophages was also 
worked out. 
The transgenic parasites with double and triple 
BT1 disruption showed a slower growth in the absence 
of biopterin and folate. Growth rate was much slower in 
the TKO disrupted mutant when compared to DKO, in 
the absence of biopterin and folate. Thus the growth of 
the parasite correlates with the biopterin transport 
potential of the BT1 gene. 
Interestingly, recombinant parasite possessing 
single, double and triple BT1 disruption showed a 
decrease in their ability to infect and survive in the 
macrophages, which correlates with the order of 
disruption. In case of TKO, there was a decrease in the 
infectivity and the number of amastigotes over a period 
of time with the number of amastigotes showing a 2.5 
fold decrease at 24 h. Addition of biopterin and folate 
to the medium restored both survival and replication of 
BT1 triple knockout strain to approximately the wild 
type levels. It is reported in earlier studies also that in L. 
major, the growth of a BT1 null mutant can be rescued 
by adding biopterin[6].  
 In order to prove that the observed decreased 
intracellular survival is due to the BT1 gene, we used 
BT1overexpressing Leishmania strain. It was observed 
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that the AG83 strain having overexpression of BT1 
gene showed increased infectivity, attachment per se in 
the macrophages as compared to the wild type AG83 
strain having no amplification of BT1 gene 
BT1 gene, which appears to be required for 
parasite survival inside the macrophages, appears to be 
an attractive target, which can be exploited to 
incapacitate the parasite to generate a live vaccine. The 
studies in this laboratory have shown that recombinant 
BT1 gene product has a potential to be developed as a 
candidate vaccine for preventing experimental 
leishmaniasis[10]. BT1 mutants used in this study also 
showed attenuated capacity to survive in the 
macrophages. Recently, it has been shown that 
genetically manipulating the pterin transporter in L. 
donovani, it is possible to generate an attenuated 
organism that could be part of a vaccination strategy[27]. 
It would be interesting to use these stable BT1 
disruption mutants in combination with other mutants 
for exploring the possibility of vaccine development for 
leishmaniasis. 
The Glucantime IC50 values were >7.5 mg/ml for 
both the wild type and TKO strain with biopterin or 
folate supplementation (7.5 µM each of biopterin and 
dihydrobiopterin, 7.5 µM each of folate and 
dihydrofolate). This similar effect by biopterin and 
folate individually on the reversal of Glucantime 
susceptibility suggests that they may both act by a 
similar mechanism.  Earlier studies have indicated that 
BT1 (ORFG) is not only a high affinity biopterin 
transporter but also transports folic acid, with a lower 
affinity[20]. A partial reversal of Glucantime 
susceptibility in Leishmania by addition of biopterin to 
the media has been observed previously[23]. In addition, 
strains that differed in fatty acid composition were 
found to differ with respect to Glucantime 
susceptibility[23]. Pterins have been implicated as 
cofactors in unsaturated fatty acids biosynthesis[8, 14]. 
Taken together, these data suggest a possible site of 
action for Glucantime within the fatty acids 
biosynthetic pathway.  The reversal of Glucantime 
susceptibility by biopterin, even in strains that are 
deficient in biopterin transport, is somewhat surprising, 
suggesting that the effect may be exerted independently 
of biopterin transport, possibly by blocking Glucantime 
uptake.  Alternatively, it is possible that a low 
intracellular level of pterins is sufficient for the reversal 
of the Glutamine susceptibility, and that even in the 
absence of the BT1-encoded biopterin transporter, 
sufficient intracellular pterins are present to exert an 
anti-Glucantime effect.  Indeed, it appears that after 
prolonged growth in culture the TKO strain is able to 
partially compensate for its lack of BT1. Consequently, 
the role of biopterin and folate in Glucantime 
susceptibility needs to be investigated further. 
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